Testing emactinib with chemo and immunotherapy before head and neck cancer surgery
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests whether combining the drug emactinib with chemotherapy and immunotherapy before surgery helps treat advanced head and neck cancer. It aims to shrink tumors and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced head and neck cancer (stage III or IVA) that can be operated on or may become operable.
- You are physically active and able to care for yourself (ECOG score 0-1).
- A blood test shows that more than 10% of your immune cells (CD8+ T cells) are a certain type that may respond to treatment.
- Your kidneys, liver, and blood cell counts are within a healthy range.
- You have not had prior treatment with immunotherapy or JAK inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of immunotherapy and chemotherapy before surgery, then immunotherapy afterwards, for head and neck cancer that has reached the skull base. The goal is to see if this approach can shrink the tumor and help improve long-term outcomes.
This trial tests a combination of targeted immunotherapy and chemotherapy given before surgery or radiation for head and neck cancer. The goal is to shrink the tumor and potentially improve outcomes.
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
Hear when a new Head and Neck Cancer Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.